文献速递其他结缔组织病

幼年皮肌炎组织特异性蛋白质组特征揭示持续疾病活动相关通路

Discovery of tissue-specific proteomic signatures in juvenile dermatomyositis highlights pathways reflecting persistent disease activity, clinical heterogeneity, and myositis-specific autoantibody subtype.
PubMed 文献 · Ann Rheum Dis · 2025-09-06

研究对56例新发幼年皮肌炎患者和8例儿科对照进行血浆蛋白质组学检测,发现尽管接受多药免疫抑制治疗,6个月时固有免疫激活、细胞死亡和氧化还原信号仍持续失调。循环内皮蛋白与疾病活动相关,NXP2+和MDA5+亚型具有不同的蛋白质组特征,分别反映血管生成/细胞外基质重塑和III型干扰素/表面活性蛋白通路。

要点

  • 56例新发JDM患者血浆3072种蛋白检测,6个月时固有免疫、细胞死亡和氧化还原信号仍持续失调。
  • 循环内皮蛋白与疾病活动相关,JDM肌肉和皮肤中验证到内皮细胞标志物表达。
  • NXP2+亚型相关蛋白反映血管生成和细胞外基质重塑;MDA5+亚型与III型干扰素和表面活性蛋白相关。

核心结论

  • 这些蛋白质组学发现将有助于未来生物标志物和治疗开发,需考虑JDM中独特的组织和自身抗体相关炎症。

研究设计与样本

  • 探索性蛋白质组学研究,纳入北美纵向队列中56例新发JDM患者(来自儿童关节炎和风湿病研究联盟注册库及3个额外中心)和8例儿科对照,在开始治疗后12周内检测血浆3072种蛋白(Olink panel)。
  • 24例JDM患者有6个月随访样本并接受评估;采用线性混合效应模型识别组间差异表达蛋白,并与经验证的疾病活动度指标关联。
  • 利用人类蛋白质图谱及JDM肌肉单核和皮肤单细胞转录组数据集评估细胞/组织特异性,并分析肌炎特异性自身抗体(MSA)亚组内差异。

主要发现

  • 尽管接受多药免疫抑制治疗,6个月时固有免疫激活、细胞死亡和氧化还原信号仍持续失调。
  • 循环内皮蛋白与疾病活动相关,并在JDM肌肉和皮肤中验证到内皮细胞标志物表达。
  • NXP2+ JDM相关蛋白反映血管生成和细胞外基质重塑,表达于内皮细胞和成纤维细胞。
  • MDA5+ JDM与循环III型干扰素和表面活性蛋白相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Juvenile dermatomyositis (JDM) is a heterogeneous autoimmune condition needing targeted treatment approaches and improved understanding of molecular mechanisms driving clinical phenotypes. We utilised exploratory proteomics from a longitudinal North American cohort of patients with new-onset JDM to identify biological pathways at disease onset and follow-up, tissue-specific disease activity, and myositis-specific autoantibody (MSA) status. METHODS: We measured 3072 plasma proteins (Olink panel) in 56 patients with JDM within 12 weeks of starting treatment (from the Childhood Arthritis and Rheumatology Research Alliance Registry and 3 additional sites) and 8 paediatric controls. Twenty-four patients with JDM who had 6-month follow-up samples were assessed. We identified differentially expressed proteins (DEPs) between groups by fitting linear mixed effects models and associated DEPs with validated disease activity measures. We assessed for cell/tissue specificity using the Human Protein Atlas and JDM muscle single nuclei and skin single-cell transcriptomic datasets. Differences within MSA subgroups were also analysed. RESULTS: We uncovered persistent dysregulation of innate immune activation, cell death, and redox signalling at 6 months despite multidrug immunosuppression. By leveraging tissue and cell-specific proteomes, we identified overrepresentation of circulating endothelial proteins associated with disease activity and verified endothelial cell marker expression in JDM muscle and skin. We discovered pathways associated with MSA subtypes that reflect JDM phenotypes. NXP2+ JDM-associated proteins reflected angiogenesis and extracellular matrix remodelling and were expressed in endothelial cells and fibroblasts. MDA5+ JDM was associated with circulating type III interferon and surfactant proteins. CONCLUSIONS: These proteomic findings will inform future biomarker and treatment development considering the unique tissue- and autoantibody-associated inflammation in JDM.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Neely J, Sabbagh SE, Dvergsten J, et al. Discovery of tissue-specific proteomic signatures in juvenile dermatomyositis highlights pathways reflecting persistent disease activity, clinical heterogeneity, and myositis-specific autoantibody subtype. Ann Rheum Dis. 2025. PMID: 40915939. doi:10.1016/j.ard.2025.07.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。